ASHG 2026 Exhibitors

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

189 organizations exhibit at ASHG 2026 — 163 companies, 13 universities and research institutes, 10 government and non-profit bodies and 3 hospitals and health systems. 73 of them also present on the scientific program, with 300 presentations between them. Most represented: National Human Genome Research Institute (42 on the program), University of Washington (39 on the program), Vanderbilt University Medical Center (20 on the program). 189 of them have their own page in this guide. As of Sep 25, 2026.

All 1,062 organizations at ASHG 2026 →

Scientific focus
Top represented
Showing 1–30 of 189 organizations
OrganizationASHG 2026 Attendance
10 Staff Scientists · 7 PIs · 5 Postdocs · 2 Clinicians
Booth
Exhibiting at Booth 208
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
University of Washington
Seattle, Washington
11 PIs · 9 PhD Students · 8 Staff Scientists · 6 Postdocs
Booth
Exhibiting (no floor booth listed)
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
5 PhD Students · 3 Postdocs · 3 Faculty · 1 PI
Booth
Exhibiting at Booth 111
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Illumina
San Diego, California
1 Senior Manager · 1 Vice President and Global Head of Advanced Science · 1 Sr Director, R&D · 1 Sr Director, Scientific Research-Advanced Platforms · 1 other presenter
Public company~8,600 people
Illumina sells DNA sequencing and array-based technologies. It serves research, clinical, and applied-market customers.
Illumina's Billion Cell Atlas alliance added AI-native drug developer Formation Bio and other members, widening its AI-biopharma customer reach.
›
Illumina's Billion Cell Atlas alliance added AI-native drug developer Formation Bio and other members, widening its AI-biopharma customer reach.
2026-07 · source
Illumina appointed Sullivan and Coletti to its executive leadership team, adding experienced decision-makers you may now be selling to.
2026-07 · source
Illumina launched StrataMap Spatial, a new whole-transcriptome spatial platform, giving customers an in-house option instead of buying elsewhere.
2026-06 · source
Source: company newsroom
Q2 2026 revenue $1.16B, up 9.5%
›
FY2026 guidance raised to $4.60-$4.64 billion, signaling steady growth and budget for sequencing purchases. · 2026-07-30
“Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025. For fiscal year 2026, we now expect total revenue of $4.60-$4.64 billion.”
Source: results release
Currently hiring
›
Source: careers page
Booth
Exhibiting at Booth 701
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
LabCorp
Burlington, Vermont
1 Lab Director · 1 Senior Applied Research Scientist in Oncology · 1 Data scientist · 1 Statistical Geneticist · 4 other presenters
Public company~71,000 people
Labcorp is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions.
Labcorp is collaborating with OHSU on a study evaluating blood-based MRD testing for earlier detection of bladder-cancer recurrence.
›
Labcorp is collaborating with OHSU on a study evaluating blood-based MRD testing for earlier detection of bladder-cancer recurrence.
2026-09 · source
Labcorp acquired MLM Medical Labs, a global central and specialty laboratory provider, expanding its central-lab capacity for trial sponsors.
2026-09 · source
Labcorp enhanced its Global Trial Connect platform, upgrading the digital tools it offers clinical-trial sponsors and data teams.
2026-08 · source
Source: company newsroom
Q2 2026 revenue $3.73B, up 5.8%
›
FY2026 revenue-growth guidance of 5.4%-6.3% points to continued expansion of its testing and trial services. · 2026-07-30
“Revenue: $3.73 billion vs. $3.53 billion, up 5.8%; Annual revenue growth guidance of 5.4% to 6.3%.”
Source: results release
Booth
Exhibiting at Booth 1024
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Ambry Genetics
Aliso Viejo, California
2 Scientists · 1 Variant Assessment Scientist · 1 Bioinformatics Scientist and Engineer · 1 Genetic Counselor · 2 other presenters
Subsidiary
Clinical genetic testing laboratory serving healthcare providers with hereditary cancer, rare disease, and specialty genomic testing.
A study found Ambry's ExomeReveal RNA testing improves diagnostic clarity for uncertain exome variants, useful evidence for their pitch.
›
A study found Ambry's ExomeReveal RNA testing improves diagnostic clarity for uncertain exome variants, useful evidence for their pitch.
2026-06 · source
Ambry's CARE Program won a 2026 MedTech Breakthrough award for best overall health informatics solution.
2026-05 · source
Ambry's MAVE research is supporting thousands of patient variant reclassifications and expanding coverage to new genes.
2026-02 · source
Source: company newsroom
Booth
Exhibiting at Booth 1201
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Regeneron
Tarrytown, New York
1 Employee · 1 Senior Manager, RGC · 1 Statistical Geneticist · 1 SVP and Chief Genomics and Data Sciences Officer
Public company~15,400 people
Regeneron invents, develops, and commercializes medicines for serious diseases. Its work spans biologics, genetic medicines, and cell therapies.
Won FDA approval for Pasatru, the first treatment for a rare bone-growth disorder called FOP, adding a new rare-disease product.
›
Won FDA approval for Pasatru, the first treatment for a rare bone-growth disorder called FOP, adding a new rare-disease product.
2026-08 · source
Launched a research collaboration with Parabilis Medicines to develop antibody-peptide conjugate therapies, expanding its drug-discovery pipeline.
2026-05 · source
Agreed to provide its newly approved genetic-hearing-loss gene therapy Otarmeni for free in the US, expanding patient access.
2026-04 · source
Source: company newsroom
Q2 2026 revenue $4.3B, up 17% YoY
›
2026 guidance includes R&D spend of $6.5-6.635 billion and SG&A of $2.83-2.96 billion. · 2026-07-30
“Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025; GAAP R&D $6.500–$6.635 billion”
Source: results release
Currently hiring: 662 open roles
›
Source: careers page
Booth
Exhibiting at Booth 507
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
4 PIs · 2 Postdocs · 2 Staff Scientists · 1 PhD Student
Booth
Exhibiting at Booth 211
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Helix
San Mateo, California
2 Senior Research Scientist · 1 Medical Director · 1 Associate Director Research · 1 Senior Staff Scientist
Private company
Helix sells population-scale genomic testing, clinico-genomic data, and research tools to health systems and life-science companies.
Helix signed a multi-year deal giving AstraZeneca access to its growing, deeply phenotyped GenoSphere cohorts for drug discovery research.
›
Helix signed a multi-year deal giving AstraZeneca access to its growing, deeply phenotyped GenoSphere cohorts for drug discovery research.
2026-07 · source
Helix launched a GenoSphere MCP connector inside Claude Science, making its genomic data directly accessible through AI tools.
2026-07 · source
Nebraska Medicine and Memorial Hermann launched Helix Genomic Advantage, a new population health system partnership improving care and lowering cost.
2026-06 · source
Source: company newsroom
Raised $50M Series C (Jun 2021)
›
Led by Warburg Pincus, DFJ Growth, Kleiner Perkins, Mayo Clinic, and Temasek; most recent disclosed round. · 2021-06-03
“The $50M round will be used to accelerate the organization's population genomics platform.”
Source: funding announcement
Booth
Exhibiting at Booth 1200
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
GeneDx
Stamford, Connecticut
1 Senior Vice President of Medical Affairs · 1 Senior Health Economics & Outcomes Research Scientist · 1 Clinical Data Scientist · 1 Senior Genetic Counselor
Public company
GeneDx sells clinical exome and genome testing, clinical interpretation, and genomic insights. It serves healthcare providers and biopharma partners.
GeneDx launched redesigned exome and genome reports to make genomic insights easier for non-genetics clinicians to use directly.
›
GeneDx launched redesigned exome and genome reports to make genomic insights easier for non-genetics clinicians to use directly.
2026-08 · source
GeneDx appointed Mark Gardner as president effective June 2026, a new leader for its next growth phase.
2026-06 · source
GeneDx and Zevra Therapeutics launched a genetic testing program for Niemann-Pick disease type C, opening a rare-disease outreach channel.
2026-03 · source
Source: company newsroom
Q2 2026 revenue $114.4M, up 11%
›
FY2026 guidance of $475M-$490M points to continued growth in exome and genome testing volume. · 2026-08-03
“Revenue grew to $114.4 million, an increase of 11% year-over-year.”
Source: results release
Booth
Exhibiting at Booth 616
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
5 PIs · 1 Staff Scientist
Booth
Exhibiting at Booth 101
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
PacBio
Menlo Park, California
1 Senior Product Manager, PacBio · 1 Bioinformatics Scientist · 1 Scientist · 1 Principal I Scientist, Bioinformatics · 1 other presenter
Public company
PacBio sells HiFi long-read sequencing systems, consumables, sample-prep kits, and analysis software to scientists and clinical researchers.
PacBio appointed Mark Van Oene as President and CEO effective August 5, 2026, a leadership change to watch during outreach.
›
PacBio appointed Mark Van Oene as President and CEO effective August 5, 2026, a leadership change to watch during outreach.
2026-08 · source
PacBio announced SPRQ-Nx chemistry and a software update for its Vega system, improving throughput and data output for HiFi sequencing.
2026-08 · source
SPRQ-Nx chemistry began shipping worldwide for PacBio's Revio platform, enabling sub-$300 HiFi genomes for large sequencing projects.
2026-05 · source
Source: company newsroom
Q2 2026 revenue $39.0M, down about 2%
›
Revenue dipped slightly year over year; FY2026 guidance is $155M-$165M, a modest growth outlook. · 2026-08-05
“"Revenue (in millions) | $39.0 | $39.8" / "PacBio expects revenue for the full year 2026 to be in the range of $155 million to $165 million."”
Source: results release
Booth
Exhibiting at Booth 605
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Genomics
Oxford, UK
1 Scientist · 1 Bioinformatician · 1 Chief Scientific Officer · 1 Research Scientist · 1 other presenter
Private company~150 people
Genomics sells AI-enabled human-genetics analytics and polygenic-risk testing to biopharma and healthcare providers.
Genomics launched Mystra AI, a human-genetics agentic AI platform for drug target discovery, already adopted by major biotechs.
›
Genomics launched Mystra AI, a human-genetics agentic AI platform for drug target discovery, already adopted by major biotechs.
2026-06 · source
Genomics partnered with Greywolf Therapeutics to research autoimmune disease targets using antigen modulation approaches.
2026-04 · source
Genomics rolled out its Health Insights predictive clinical tool nationwide across Great Britain, with new locations onboarding weekly.
2025-06 · source
Source: company newsroom
Raised $30M funding round (Mar 2021)
›
Backed significantly by Foresite Capital and F-Prime Capital; the most recent disclosed round. · 2021-03-01
“it has successfully completed a $30m funding round; Significant investment from leading life science investors Foresite Capital and F-Prime Capital.”
Source: funding announcement
Currently hiring
›
Source: careers page
Booth
Exhibiting at Booth 1418
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
2 Principal Applications Bioinformatician · 1 Senior Bioinformatician, Commercial Applications · 1 Senior Director of Commercial Applications · 1 Associate Director, Genomic Applications Bioinformatics
Public company~1,000 people
Oxford Nanopore sells real-time DNA/RNA sequencing devices, flow cells, and analysis software. Its customers include research, clinical, and biopharma teams.
Oxford Nanopore appointed David Miller as chief development and product officer and Conor McKechnie as chief marketing officer.
›
Oxford Nanopore appointed David Miller as chief development and product officer and Conor McKechnie as chief marketing officer.
2026-08 · source
Oxford Nanopore's MATRIX collaboration expanded to national CNS tumour classification across Norway, broadening its clinical sequencing reach.
2026-06 · source
Lonza and Oxford Nanopore launched a direct RNA sequencing solution for GMP mRNA quality control, opening an mRNA-manufacturing market.
2026-05 · source
Source: company newsroom
H1 2026 revenue £116.7M, up 10.5%
›
FY26 guidance is 16-20% constant-currency growth, excluding one-time $20M in licensing revenue. · 2026-08-19
““Group revenue was £116.7 million, which grew by 12.3% on a constant currency basis (CC), and 10.5% on a reported basis” / “FY26 revenue (no change): Constant-currency growth of 16–20%, excluding the $20 million non-recurring revenue””
Source: results release
Booth
Exhibiting at Booth 901
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
1 PI · 2 announced attending
Booth
Exhibiting (no floor booth listed)
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Nabsys
Dallas, Texas
2 Application Scientist · 1 Software Product Manager · 1 Principal Scientist
Subsidiary
Nabsys provides electronic genome mapping tools for research laboratories. Its OhmX Platform combines an analyzer, consumables, and software for structural-variant analysis.
Nabsys began a multi-year research collaboration with Indiana University School of Medicine on hematologic malignancy applications for its OhmX platform.
›
Nabsys began a multi-year research collaboration with Indiana University School of Medicine on hematologic malignancy applications for its OhmX platform.
2026-07 · source
Nabsys signed a lease for a new 30,000-square-foot headquarters in Providence, signaling company growth and expansion plans.
2026-07 · source
Nabsys appointed Alka Chaubey as chief medical and genomics officer, adding a genome-mapping veteran to its leadership team.
2026-07 · source
Source: company newsroom
Raised $38M expanded equity round (Nov 2022)
›
Included an additional $13M from Hitachi High-Tech as part of the expanded round. · 2022-11-09
“announced today that it has received an additional $13 million from Hitachi High-Tech as part of an expanded equity round now totaling $38 million.”
Source: funding announcement
Currently hiring: 7 open roles
›
Source: careers page
Booth
Exhibiting at Booth 501
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Agilent Technologies
Santa Clara, California
2 R&D Scientist · 1 Product Marketing Director · 1 Product Manager
Public company~18,000 people
Agilent sells instruments, software, and consumables to laboratories. It also provides genomics assays, sample QC, and workflow services for research and diagnostics.
Agilent's board chair Koh Boon Hwee retired effective September 2026; Glenn Boehnlein joined the board, a leadership shift.
›
Agilent's board chair Koh Boon Hwee retired effective September 2026; Glenn Boehnlein joined the board, a leadership shift.
2026-09 · source
Agilent launched the S540MD digital pathology slide scanner in the US, adding a new pathology imaging product.
2026-09 · source
Agilent introduced the Cary 635 FTIR spectrometer, a new analytical instrument expanding its lab hardware lineup.
2026-09 · source
Source: company newsroom
Q3 FY2026 revenue $1.88B, up 8.1%
›
FY2026 revenue guidance is $7.49B-$7.51B, indicating steady growth across its instrument and consumables business. · 2026-08-26
“Revenue of $1.88 billion for the third quarter ended July 31, 2026, representing growth of 8.1% reported and up 7.3% core. Fiscal year 2026 revenue is now expected in the range of $7.49 billion to $7.51 billion.”
Source: results release
Currently hiring
›
Source: careers page
Booth
Exhibiting at Booth 1017
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Element Biosciences
San Diego, California
1 Scientist I · 1 Vice President Research And Development · 1 Sr Director of Strategic Marketing · 1 other presenter
Private company~300 people
Element Biosciences sells sequencing instruments, reagents, and multiomics workflows to research, pharmaceutical, biotechnology, and clinical laboratories.
Element Biosciences appointed global biopharma R&D leader Mikael Dolsten to its board, adding pharma-industry perspective to strategy.
›
Element Biosciences appointed global biopharma R&D leader Mikael Dolsten to its board, adding pharma-industry perspective to strategy.
2026-08 · source
Element introduced VITARI, a high-throughput benchtop sequencer it says can deliver a whole genome for $100, a competitive pricing move.
2026-02 · source
Element launched a Teton certified-provider program for CytoProfiling on its AVITI24 platform, opening a services channel for partners.
2025-12 · source
Source: company newsroom
Raised $175M+ Series E (Jun 2026)
›
Samsung Electronics, a longstanding investor, contributed $175 million; other investors added an undisclosed amount. · 2026-06-09
“including $175 million from longstanding investor Samsung Electronics, and an undisclosed amount from other investors.”
Source: funding announcement
Booth
Exhibiting at Booth 1108
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Thermo Fisher Scientific
Carlsbad, California
1 Senior Manager, Bioinformatics Microarray · 1 Sr. Staff Scientist · 1 Senior Product Marketing Manager · 1 Scientist
Public company~120,000 people
Thermo Fisher sells genomic and proteomic instruments, assays, and reagents. It serves research labs, clinical laboratories, and biopharma customers.
Thermo Fisher launched the PPD CorEvitas Chronic Hand Eczema Registry, a new real-world data source for dermatology research.
›
Thermo Fisher launched the PPD CorEvitas Chronic Hand Eczema Registry, a new real-world data source for dermatology research.
2026-06 · source
Thermo Fisher unveiled next-generation Orbitrap platforms and AI analytics at ASMS 2026, aimed at accelerating drug discovery to therapy.
2026-05 · source
Thermo Fisher partnered with PRECISE-SG100K in Singapore to advance population-scale proteomics, expanding its global biobank leadership.
2026-04 · source
Source: company newsroom
Q2 2026 revenue $11.99B, up 10%
›
Q2 2026 revenue: $11.99 billion, up 10% year over year. · 2026-07-23
“Second quarter revenue grew 10% to $11.99 billion”
Source: results release
Booth
Exhibiting at Booth 1001
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
2 PIs · 1 PhD Student
Booth
Exhibiting at Booth 320
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
23andMe
Palo Alto, California
1 Senior Scientist · 1 Vice President of Genomic Health and Chief Medical Officer · 1 Applied Scientist
Non-profit
23andMe sells consumer genetic testing, ancestry reports, and health memberships. It provides genomic data, research services, and participant recruitment to biopharma partners.
23andMe Research Institute partnered with HealthEx to connect members' medical records with their DNA data.
›
23andMe Research Institute partnered with HealthEx to connect members' medical records with their DNA data.
2026-05 · source
Researchers, together with Harvard and the Smithsonian, linked a 17th-century Maryland settlement's DNA to 1.3 million living relatives.
2026-05 · source
Launched a GLP-1 weight-loss and nausea genetics report for Total Health members, based on genetics and clinical factors.
2026-04 · source
Source: company newsroom
Currently hiring
›
Source: careers page
Booth
Exhibiting at Booth 400
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Centogene
Rostock, Germany
1 Senior Product Manager · 1 Vice President Medical Genetics · 1 Chief Medical and Genomic Officer
Private company
CENTOGENE sells clinical genetic diagnostics and genomic knowledge software to physicians, patients, and pharma partners.
CENTOGENE expanded its rare-disease collaboration in Taiwan through a new program with TFRD, broadening its APAC footprint.
›
CENTOGENE expanded its rare-disease collaboration in Taiwan through a new program with TFRD, broadening its APAC footprint.
2026-08 · source
CENTOGENE acquired Pearl Medical Analysis Laboratory in Abu Dhabi, expanding its regional diagnostic lab presence.
2026-07 · source
CENTOGENE launched CentoScreen Exome, a new option expanding its reproductive carrier screening portfolio.
2026-05 · source
Source: company newsroom
Raised ~$20M from Lifera (May 2024)
›
Structured as an accounts-receivable purchase plus increased joint-venture investment to strengthen cash position. · 2024-05-15
“provides funding in aggregate of approximately $20 million to CENTOGENE”
Source: funding announcement
Booth
Exhibiting at Booth 1301
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
seqWell
Beverly, Massachusetts
1 Scientist · 1 Senior Scientist · 1 Team Lead
seqWell sells NGS library-prep kits, multiplexing kits, and transposase reagents for academic, institutional, and genomics research labs.
seqWell launched MosaiX, a next-generation DNA library prep kit for high-performance NGS applications, a new product option for labs.
›
seqWell launched MosaiX, a next-generation DNA library prep kit for high-performance NGS applications, a new product option for labs.
2026-02 · source
seqWell launched AgriPrep, a new low-coverage whole-genome library prep kit extending its TnX transposase product line.
2026-01 · source
seqWell partnered with ABL Diagnostics to develop and commercialize a library-prep technology for infectious-disease NGS testing.
2025-11 · source
Source: company newsroom
Raised $7M Series C (Apr 2022)
›
Led by Codexis with a $5M investment; RCT and BroadOak also participated in the round. · 2022-04-21
“As part of this partnership, Codexis led seqWell’s $7 million Series C financing with a $5 million investment.”
Source: funding announcement
Currently hiring: 3 open roles
›
Source: careers page
Booth
Exhibiting at Booth 1408
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
MicroPure Genomics
San Diego, California
1 CEO & Co-Founder · 1 Head of Science · 1 CRO/COO
MicroPure Genomics develops µPrep, a beadless sample-preparation platform for DNA and RNA testing across ultra-long to short-read sequencing workflows.
The National Science Foundation awarded MicroPure Genomics $250,000 for an SBIR Phase II commercial-partnership supplement, funding continued development.
›
The National Science Foundation awarded MicroPure Genomics $250,000 for an SBIR Phase II commercial-partnership supplement, funding continued development.
2026-08 · source
The NIH awarded MicroPure Genomics a $300,000 SBIR Phase I grant, early non-dilutive funding for its sample-prep platform.
2025-09 · source
MicroPure Genomics joined EvoNexus, a top California incubator for early-stage companies, signaling a startup still building out its business.
2025-07 · source
Source: company newsroom
$250K NSF SBIR Phase II award (Aug 2026)
›
A grant, not equity funding; no venture round or valuation has been disclosed. · 2026-08-13
“National Science Foundation Awards MicroPure Genomics $250,000 SBIR Phase II Technology Enhancement for Commercial Partnerships (TECP)”
Source: funding announcement
Booth
Exhibiting at Booth 1029
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Ultima Genomics
Fremont, California
1 Senior Staff NGS Application Manager · 1 Senior Bioinformatics Scientist · 1 Vice President, Germline Genomics & Distinguished Scientific Fellow
Ultima Genomics sells sequencing platforms, library-prep workflows, and bioinformatics for high-throughput omics research and healthcare.
Raised over $700M total to date
›
No specific last funding round or date is disclosed; the $700M figure is a cumulative total.
“To date, we’ve raised over $700 million from partners who share our vision.”
Source: funding announcement
Currently hiring
›
Source: careers page
Booth
Exhibiting at Booth 1009
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
1 PI
Booth
Exhibiting at Booth 310
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
biomodal
Saffron Walden, UK
1 Regional Head of Sales, North America · 1 US Territory Manager, Northeast
biomodal sells multiomic sequencing workflows and analysis software to life scientists and clinical developers.
biomodal launched duet mosaic, two new cfDNA-optimized multiomic sequencing workflows for liquid biopsy, extending its methylation product line.
›
biomodal launched duet mosaic, two new cfDNA-optimized multiomic sequencing workflows for liquid biopsy, extending its methylation product line.
2026-08 · source
biomodal's duet multiomic solutions are now compatible with Element Biosciences' AVITI24 and AVITI sequencing instruments, widening its installed base.
2026-02 · source
biomodal launched a Certified Service Provider program with global partners for its duet multiomics sequencing solutions.
2025-10 · source
Source: company newsroom
Raised $88M Series D (Nov 2021)
›
Led by Temasek; brought total funding raised to $146 million as of that round. · 2021-11-02
“today announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million.”
Source: funding announcement
No openings posted
Booth
Exhibiting at Booth 1409
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Broad Clinical Labs
Burlington, Vermont
1 Director of Clinical Product Development and Strategy · 1 Principal Product Development Scientist
Subsidiary~240 people
Broad Clinical Labs provides integrated multi-omic data generation and advanced analysis services for research and clinical applications.
The Catalyst program, led by Southern Research, MyOme, and Broad Clinical Labs, expanded free genetic testing access across Alabama.
›
The Catalyst program, led by Southern Research, MyOme, and Broad Clinical Labs, expanded free genetic testing access across Alabama.
2026-02 · source
Broad Clinical Labs set a Guinness World Record for the fastest DNA sequencing technique, a technical credibility marker.
2025-10 · source
Boston Children's Hospital, Dana-Farber, and Broad Clinical Labs launched BrightSeq, a pediatric cancer genomics research and testing initiative.
2025-08 · source
Source: company newsroom
Booth
Exhibiting at Booth 927
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
EpiCypher
Durham, North Carolina
1 Product Manager · 1 Associate Director of Product Development
EpiCypher sells chromatin-mapping assays, designer nucleosomes, and bioinformatics platforms to academic, biotech, and pharmaceutical researchers.
Abcam and EpiCypher partnered to deliver validated antibodies with ChIC/CUT&RUN technology, pairing reagents to speed epigenomic research workflows.
›
Abcam and EpiCypher partnered to deliver validated antibodies with ChIC/CUT&RUN technology, pairing reagents to speed epigenomic research workflows.
2026-07 · source
EpiCypher expanded its strategic partnership with New England Biolabs to advance epigenomics research together.
2026-05 · source
EpiCypher launched a CUTANA Fiber-seq kit aimed at making single-molecule chromatin mapping more accessible to more labs.
2025-11 · source
Source: company newsroom
Booth
Exhibiting at Booth 416
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Fulcrum Genomics
Somerville, Massachusetts
1 Founding Partner · 1 Principal Bioinformatics Scientist
Private company~14 people
Bioinformatics consulting, custom tools, pipelines, and systems for biotech, pharma, life-science, and diagnostic teams.
Backed minibwa, a new project aiming to speed up read alignment, one of genomics' most widely used computing steps.
›
Backed minibwa, a new project aiming to speed up read alignment, one of genomics' most widely used computing steps.
2026-06 · source
Introduced Riker, a modern successor to the widely used Picard tool for sequencing quality-control metrics.
2026-04 · source
Introduced fgumi, a new UMI toolkit still in alpha, being tested across several vendors' sequencing datasets.
2026-03 · source
Source: company newsroom
No openings posted
Booth
Exhibiting at Booth 1224
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm

Explore the full ASHG 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Montréal. Leave your work email and we’ll be in touch.

Privacy

Download the full ASHG 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from ASHG 2026 exhibitors

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Browse ASHG 2026 by

Exhibit hall
  • Exhibitors 189

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction